Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
Clinical trial NCT05707325 · UNKNOWN
Trial details
- NCT number
- NCT05707325
- Sponsor
- Westlake Therapeutics
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-16
- Primary completion
- 2025-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.